Protara Therapeutics (TARA) Income towards Parent Company (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Income towards Parent Company data on file, last reported at -$28.9 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 58.4% year-over-year to -$28.9 million in Q1 2026; TTM through Mar 2026 was -$88.8 million, a 52.32% decrease from a year earlier, with the FY2025 full-year figure at -$148.1 million, down 25.13% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$28.9 million, down from -$19.5 million in the prior quarter.
• Over the last five years, Income towards Parent Company for TARA reached as high as -$9.1 million in Q3 2022 and fell as low as -$40.1 million in Q4 2022.
• Historically, Income towards Parent Company has averaged -$16.5 million across 5 years, with a median of -$13.4 million in 2023.
• Across the five-year window, Income towards Parent Company slumped 225.29% in 2022 and jumped 67.56% in 2023, its largest moves.
• Year by year, Income towards Parent Company stood at -$40.1 million in 2022, then soared by 67.56% to -$13.0 million in 2023, then gained by 12.45% to -$11.4 million in 2024, then tumbled by 71.29% to -$19.5 million in 2025, then slumped by 48.42% to -$28.9 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$28.9 million in Q1 2026, -$19.5 million in Q4 2025, and -$19.4 million in Q3 2025.